Date: 2016-03-23
Type of information: Grant
Company: Polyphor (Switzerland)
Investors: Cystic Fibrosis Foundation Therapeutics (USA - MD)
Amount: $3 million
Funding type: grant
Planned used: The award will be used to advance the clinical development of the inhaled elastase inhibitor POL6014 in cystic fibrosis. POL6014 reduces the activity of elastase, an enzyme that destroys lung tissue when it is produced in excess. Polyphor initiated a Phase I study of POL6014 in healthy volunteers using a customized Pari eFlow® aerosol inhaler. A single ascending dose study in the EU is planned to evaluate the safety and tolerability of POL6014 in individuals with cystic fibrosis followed by a 28-day multiple ascending dose study. These studies aim to further assess the drug’s safety, as well as the impact on a range of biomarkers and on lung function.
Others: * On March 23, 2016, Polyphor announced an agreement with Cystic Fibrosis Foundation Therapeutics to advance the clinical development of POL6014 in cystic fibrosis.
Therapeutic area: Rare diseases - Genetic diseases
